16 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 WuXi XDC, a CRDMO specializing in antibody-drug conjugates (ADCs) and other bioconjugates, and Earendil Labs, a biotech company advancing biologics for the treatment of autoimmune diseases, cancer, and other conditions with unmet medical needs, announced a strategic collaboration on February 27th, 2026. The deal grants Earendil an exclusive global license to the WuXiTecan-2 payload-linker technology platform for use in its drug development program. In return, WuXi XDC will be eligible for up to approximately $885 million in upfront and milestone payments, as well as tiered royalties on net sales of any resulting products. According to a company press release, Earendil will use WuXi’s technology to conjugate antibodies and bispecific antibodies for multiple specific targets discovered through its AI platform. Additionally, WuXi XDC will support the CMC development and manufacturing of the ADC components within the collaboration, while Earendil will focus on subsequent product development, global regulatory submissions, and commercialization. “We are very pleased to establish this strategic partnership with Earendil Labs. This collaboration not only fully demonstrates the value of our WuXiTecan-2 payload-linker technology platform but also marks another significant milestone for WuXi XDC in empowering cutting-edge innovation alongside our partners,” said Jimmy Li, PhD, CEO, WuXi XDC, in the release. “Earendil Labs has generated bispecific antibodies with differentiated advantages using its unique AI platform. Combining these with our WuXiTecan-2 technology helps develop more effective and safer next-generation ADCs. We look forward to supporting Earendil Labs in accelerating the R&D and commercialization of their ADCs through our integrated, end-to-end CRDMO service platform, ultimately benefiting patients worldwide.” “Partnering with WuXi XDC represents a critical step in our mission to transform biopharmaceutical R&D through AI. WuXi XDC possesses a globally recognized and validated ADC technology platform and end-toend manufacturing capabilities,” said Jian Peng, PhD, CEO, Earendil Labs, in the release. “This collaboration is a powerful alliance between frontier AI exploration and WuXi XDC’s integrated CRDMO services. We eagerly anticipate working closely with WuXi XDC to drive innovative breakthroughs through technological integration, empowering high-quality development in the global biopharma industry and contributing to the health of patients globally.” “ADCs are emerging as a promising class of therapeutics in the treatment of cancer and many other human diseases,” said Zhenping Zhu, MD, PhD, President & co-CEO of Earendil Labs, in the release. “At Earendil Labs, we are developing a rich pipeline of bispecific / multispecific ADCs utilizing our cuttingedge AI and high-throughput biology [platforms]. We believe WuXiTecan-2 payload-linker technology will significantly enhance the success rate and speed of our novel ADC development, ultimately bringing these potentially life-transforming treatments to patients worldwide as soon as possible.” WuXi XDC strikes $885 million ADC deal with Earendil Labs NEWS Argo Biopharma appoints Dr. Gena Wang as CFO and CSO Argo Biopharma, a clinical-stage biotechnology company advancing next-generation siRNA therapies, announced the appointment of Dr. Gena Wang as Chief Financial Officer and Chief Strategy Officer on March 2nd, 2026. Dr. Wang joins Argo from Barclays, where she served as Managing Director,
RkJQdWJsaXNoZXIy MjY2OTA4MA==